Bacillus megaterium MIT411 Colonization Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of Bacilli are not sufficiently efficient in recolonizing in vivo microbial ecosystems, necessitating the identification of strains with enhanced colonization abilities.
Innovation Solution
The use of Bacillus megaterium strain MIT411 alone or in combination with other Bacilli strains, such as Bacillus coagulans and Bacillus clausii, which possess properties like bile stability, acid stability, heat tolerance, and antimicrobial activity, to enhance colonization and treat various infections and diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions of Bacilli are used, then probiotic treatment is provided, but colonization efficiency in vivo is insufficient
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing specific Bacillus strains (Bacillus coagulans CGI314, Bacillus clausii CSI08, and Bacillus megaterium MIT411) with optimized physiological parameters including bile salt resistance, acid stability, and heat tolerance. These parameter optimizations enable the strains to survive gastrointestinal conditions and effectively colonize the intestinal tract, directly resolving the contradiction between providing probiotic treatment and achieving sufficient colonization efficiency.
2Reliability
If Bacillus strains are administered to treat dysbiosis, then intestinal flora regeneration is possible, but the strains must survive harsh gastrointestinal conditions
Solution Approach 1:
The patent applies beforehand cushioning by formulating the Bacillus strains with protective mechanisms that enable them to withstand gastrointestinal stress before administration. The selected strains possess inherent resistance to bile salts, stomach acid, and heat, which cushion them against the harmful gastrointestinal environment. Additionally, the strains produce protective substances such as bacteriocins and organic acids that further protect them during transit through the gastrointestinal tract, ensuring they reach the intestinal tract alive to regenerate flora.
3Reliability
If probiotic Bacilli are used to prevent infections, then antimicrobial activity is provided, but competitive adhesion to epithelium is required
Solution Approach 1:
The patent applies merging by combining multiple functional properties in single Bacillus strains. The selected strains simultaneously exhibit antimicrobial activity (producing bacteriocins, organic acids, and hydrogen peroxide) and strong adhesion capabilities (binding to intestinal epithelium and mucus). This merging of functions allows the strains to both prevent pathogen growth through antimicrobial substances and establish stable colonization through adhesion, resolving the contradiction between providing antimicrobial activity and achieving ease of operation in terms of adhesion capability.
Data Source
AI summary
The invention provides a Bacillus megaterium strain comprising a purified microbial population that comprises one or more bacteria with a gyrB that shares at least 97% identity with SEQ ID NO: 1; and/or that comprises one or more bacteria with a 16S rRNA that shares at least 97% identity with SEQ ID NO: 2. Optionally, the Bacillus megaterium strain shares at least 97% identity with SEQ ID NO: 3. The strain may be used in compositions and methods.